Managed Care

A Phase II Trial Finds Ixekizumab “Extremely Effective” and Safe for Psoriasis

Kenneth Gordon, Professor of Dermatology at Northwestern University, discusses phase II safety and efficacy studies of the anti–interleukin-17 monoclonal antibody ixekizumab for psoriasis. In a year-long extension of a 12-week trial, ixekizumab was “extremely effective” at sustaining responses, leading to complete clearance in 40% to 50% of patients. The drug was also very well tolerated, with no safety signals that raised concern.